Genomic correlates of leptomeningeal disease after brain metastasis resection.

Roshal R. Patel(Memorial Sloan Kettering Cancer Center), Luke Pike(Memorial Sloan Kettering Cancer Center), Walid K. Chatila(Memorial Sloan Kettering Cancer Center), Kenny Yu(Memorial Sloan Kettering Cancer Center), Emily Miao(Albert Einstein College of Medicine), Anna Skakodub(Icahn School of Medicine at Mount Sinai), Nelson S. Moss(Memorial Sloan Kettering Cancer Center), Chengcheng Gui(Memorial Sloan Kettering Cancer Center), N. Schultz(Memorial Sloan Kettering Cancer Center), James Lee(Memorial Sloan Kettering Cancer Center), Zachariya Yazdani(Memorial Sloan Kettering Cancer Center), Ramzi Homsi(Memorial Sloan Kettering Cancer Center), Joseph Stember(Memorial Sloan Kettering Cancer Center), Rabih Bou Nassif(Memorial Sloan Kettering Cancer Center), Pedram Razavi(Memorial Sloan Kettering Cancer Center), Jessica Wilcox(Memorial Sloan Kettering Cancer Center), Mitchell Parker(Memorial Sloan Kettering Cancer Center), Henry Walch(Memorial Sloan Kettering Cancer Center), Gustav Cederquist(Memorial Sloan Kettering Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center)
Journal of Clinical Oncology
May 27, 2026
10.1200/jco.2026.44.16_suppl.2032
Cited by 0

Related Papers

Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
|Cancer Cell|2018|718
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|Annals of Oncology|2020|443
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
|Annals of Oncology|2019|413
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413